Search
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigationalFremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches.
Products: AJOVY 225 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 3 ADET, AJOVY 225 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETVinblastine
go.drugbank.com/drugs/DB00570ApprovedInvestigationalAntitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Categories: Heterocyclic Compounds, 2-Ring, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VINBLASTINA10 MG X 1 FCO., VINCABLAS® 10 MG/VIALStage II Follicular Lymphoma
go.drugbank.com/conditions/DBCOND0080969Drugs: ObinutuzumabSynonyms: Stage 2 Follicular Lymphoma ( FL)Burosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalBurosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic … This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets.
Categories: Fibroblast Growth Factor-23 Blocking AntibodiesProducts: CRYSVITA® SOLUCIÓN PARA INYECCIÓN 20 MG/ML, CRYSVITA® SOLUTION FOR INJECTION 20 MG/MLRisdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigational[L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless
Categories: MATE 2 Inhibitors, Survival of Motor Neuron 2 Splicing ModifierProducts: Evrysdi Powder for oral solution 0.75 mg/mL, EVRYSDI POWDER FOR ORAL SOLUTION 0.75 MG/MLEtoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalEtoposide acts primarily in the G2 and S phases of the cell cycle. … A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one, 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. … Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor
Products: ERBITUX ® 5 MG/ML, ERBITUX® 5 MG/MLSennosides
go.drugbank.com/drugs/DB11365ApprovedInvestigationalSennoside A, one of the sennosides present in the laxative medication, has recently proven effective in inhibiting the ribonuclease H (RNase H) activity of human immunodeficiency virus (HIV) reverse transcriptase … It is a weaker laxative than bisacodyl or castor oil[A177092].
Salts: Sennosides A and BMixtures: BEKUNIS 3 MG/5 MG KAPLI TABLET, 30 ADET, Sennosides 8.6 Mg and Docusate Sodium 50 Mg TabletsQuinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. … Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer.
Categories: Heterocyclic Compounds, 2-Ring, Dopamine D2 Receptor AgonistsSynonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideFluoxetine
go.drugbank.com/drugs/DB00472ApprovedInvestigationalVet approvedFluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI).
Mixtures: TARGET 3 MG /25 MG KAPSUL, 90 ADET, TARGET 6 MG /25 MG KAPSUL, 90 ADETCategories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates